Anavex Life Sciences Corp. (NASDAQ:AVXL) Short Interest Update

Anavex Life Sciences Corp. (NASDAQ:AVXL) was the target of a large growth in short interest in July. As of July 31st, there was short interest totalling 19,880,000 shares, a growth of 7.8% from the July 15th total of 18,440,000 shares. Based on an average daily trading volume, of 1,220,000 shares, the short-interest ratio is presently 16.3 days.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AVXL. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research report on Thursday, August 1st. EF Hutton Acquisition Co. I raised Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd.

Hedge Funds Weigh In On Anavex Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company boosted its stake in shares of Anavex Life Sciences by 8.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,510 shares of the biotechnology company’s stock worth $129,000 after buying an additional 2,401 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new position in shares of Anavex Life Sciences in the 2nd quarter worth approximately $346,000. AQR Capital Management LLC boosted its stake in shares of Anavex Life Sciences by 145.8% in the 2nd quarter. AQR Capital Management LLC now owns 45,219 shares of the biotechnology company’s stock worth $191,000 after buying an additional 26,821 shares during the last quarter. Squarepoint Ops LLC purchased a new position in shares of Anavex Life Sciences in the 2nd quarter worth approximately $191,000. Finally, Marshall Wace LLP purchased a new position in shares of Anavex Life Sciences in the 2nd quarter worth approximately $166,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Performance

Shares of AVXL opened at $6.09 on Monday. The stock has a 50 day moving average price of $5.23 and a two-hundred day moving average price of $4.84. The firm has a market capitalization of $515.47 million, a P/E ratio of -12.18 and a beta of 0.63. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same period in the prior year, the business earned ($0.14) EPS. On average, equities analysts forecast that Anavex Life Sciences will post -0.55 earnings per share for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.